Replimune
Business Services · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
500 Unicorn Park Dr Fl 3, Woburn, Massac...Phone Number
(339) 970-2843Website
www.replimune.comRevenue
$101.2 MillionStock Symbol
REPLIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
3
3
1
1
2
About Replimune
Replimune Group, based in Massachusetts, is a company specializing in cancer therapy and developing immunotherapies that focus on improving anti-tumor effects of the chosen, patient specific immunotherapy as well as the potency of the immune systems response.Explore more
Replimune Org Chart
RN
Executive Director
RB
Executive Director, Program Management & Port...
JZ
Senior Director, Manufacturing
GT
Senior Director, Corporate Quality Systems
DU
Senior Director, Clinical Science
SC
Senior Director, Regulatory Operations
CK
Director, Quality Projects & Continuous Impro...
LO
Director, Program Management
BP
Director
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Replimune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Replimune is spiking on competitors!
Website visits: Recent activity has been detected on your website
Replimune, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Replimune recently announced quarterly report
Product Launch: Get notified when Replimune launches new products
Funding: Get notified immidiatlly once Replimune has new funding data
Congratulate Masked Content for being promoted to Masked Content at Replimune
Click to see if Replimune had a recent Job posting/layoffs
Check if Replimune has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Replimune as Masked Content
Find more new buyers
Compare Similar Companies to Replimune
Compare insights from companies similar to Replimune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Replimune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Replimune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Replimune.
Replimune financials insights
Gather financial insights about Replimune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$30M
2017
Series B
$55M
2018
Stock Offering
$111M
2019
Stock Offering
$80M
2020
Stock Offering
$100M
Replimune Tech Stack
A closer look at the technologies used by Replimune
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Pharmaceuticals, Regulations
Person-Based
Pharmaceuticals
Replimune News & Media
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
FDA decision expected by August 2, 2026 FDA decision expected by August 2, 2026Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting.Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Replimune
Sign Up For FreeTo access detailed company insights
Replimune Group, based in Massachusetts, is a company specializing in cancer therapy and developing immunotherapies that focus on improving anti-tumor effects of the chosen, patient specific immunotherapy as well as the potency of the immune systems response.... Read More
